Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Update on renal cell carcinoma].

Alain Ravaud1, Jacques-Olivier Bay

  • 1Institut Bergonié, Centre régional de lutte contre le cancer, 229, cours de l'Argonne, 33076 Bordeaux Cedex. ravaud@bergonie.org

Bulletin Du Cancer
|February 16, 2002
PubMed
Summary

This study reviews radiofrequency ablation and cellular therapies for renal cell carcinoma (RCC) from 2000-2001. It also explores hypertension, chromosomal changes, and incidentally detected tumors in relation to RCC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

European journal of cancer (Oxford, England : 1990)·2026
Same author

[Do chemotherapies still have a place in the era of precision medicine?]

Bulletin du cancer·2026

Area of Science:

  • Oncology
  • Nephrology
  • Immunotherapy

Context:

  • Focuses on primary renal tumors and renal cell carcinoma (RCC) treatment advancements during 2000-2001.
  • Examines the evolving landscape of RCC management, including surgical and cellular-based approaches.

Purpose:

  • To present key findings on radiofrequency tissue ablation for primary renal tumors.
  • To highlight cellular therapies, including dendritic cells and nonmyeloablative allogeneic transplantation, in RCC treatment.
  • To discuss associated factors such as hypertension, chromosomal abnormalities, and the prognosis of incidentally detected renal tumors.

Summary:

  • Key results include the application of radiofrequency tissue ablation for primary renal tumors.
  • Cellular therapies, specifically dendritic cells and nonmyeloablative allogeneic transplantation, are presented as significant findings.
  • Additional discussions cover hypertension as an RCC risk factor, chromosomal events in RCC development, and the prognosis of incidentally detected renal tumors.

Impact:

  • Provides insights into specific therapeutic modalities and risk factors for renal cell carcinoma.
  • Contributes to understanding the clinical context and prognostic indicators for renal tumors.
  • Informs on the early 21st-century approaches to managing renal cell carcinoma.

Related Experiment Videos